Advanced search
Publication Cover
Scandinavian Journal of Urology Volume 51, 2017 - Issue 5
Journal homepage
177
Views
1
CrossRef citations to date
0
Altmetric
Original Article

Clinical practice of BOTOX® treatment for overactive bladder syndrome in Sweden: an assessment of resource use and external validity

Katarina GralénIHE, The Swedish Institute for Health Economics, Lund, Sweden; Correspondence[email protected]
View further author information
,
Caroline ElmérStockholm Urogynecological Clinic, Stockholm, Sweden; View further author information
,
Eva BroströmDepartment of Urology, Skåne University Hospital, Malmö, SwedenView further author information
,
Rikard AlthinIHE, The Swedish Institute for Health Economics, Lund, Sweden; View further author information
&
Lars MalmbergDepartment of Urology, Skåne University Hospital, Malmö, SwedenView further author information
Pages 397-401 | Received 08 Nov 2016, Accepted 13 May 2017, Published online: 05 Jul 2017

References

  • Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the international continence society. Urology. 2003;61:37–49.
  • Irwin DE, Mungapen L, Milsom I, et al. The economic impact of overactive bladder syndrome in six western countries. BJU Int. 2008;103:202–209.
  • Medical Products Agency. Information från Läkemedelsverket [Information from the Medical Products Agency]. 2011 April 22.
  • Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008;54:543–562.
  • Abrams P, Freeman R, Anderström C, et al. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol. 1998;81:801–810.
  • Appell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology. 1997;50:90–96.
  • Drutz HP, Appell RA, Gleason D, et al. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct. 1999;10:283–289.
  • Kreder K, Mayne C, Jonas U. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder. Eur Urol. 2002;41:588–595.
  • Khullar V, Amarenco G, Angulo J, et al. Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol. 2013;63:283–295.
  • Brubaker L, Richter HE, Visco A, et al. Refractory idiopathic urge urinary incontinence and botulinum a injection. J Urol. 2008;180:217–222.
  • Sahai A, Khan MS, Dasgupta P. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol. 2007;177:2231–2236.
  • Medical Products Agency. Läkemedelsverket informerar 2013/7 [The Medical Products Agency informs 2013/7]. 2013.
  • LIF. FASS [Swedish medical product list] 2015 [last accessed 2015-05-09]. Available from: www.fass.se
  • Ruffion A, Velard M, Loveman C, et al. Cost-effectiveness comparison of botulinum toxin type a plus best supportive care versus best supportive care alone in the treatment of idiopathic overactive bladder with urinary incontinence among patients not adequately managed by anticholinergic therapy in france. Value Health. 2014;17:A470.
  • Freemantle N, Khalaf K, Loveman C, et al. OnabotulinumtoxinA in the treatment of overactive bladder: a cost-effectiveness analysis versus best supportive care in England and Wales. Eur J Health Econ. 2016;17:911–921.
  • Rothwell PM. External validity of randomised controlled trials: “To whom do the results of this trial apply?” Lancet. 2005;365:82–93.
  • Södra Regionvårdsnämnden. Regionala priser och ersättningar för södra sjukvårdsregionen [Regional prices and reimbursements for the Southern health care region]. 2015.
  • Region Skåne. Produktfakta inkontinens. rev 2015-06-25 [Product facts incontinence]. 2015.
  • Riksbanken. Annual average exchange rates (aggregate). [Internet]. 2015. Available from: http://www.riksbank.se/en/Interest-and-exchange-rates/Annual-aggregate-Exchange-rates/?y=2015&m=12&s=Comma
  • Allergan. [Data on file] Pooled dataset 520/095/096. 2013.
  • Sievert K, Chapple C, Herschorn S, et al. OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder. Int J Clin Pract. 2014;68:1246–1256.
  • Allergan. [Internet]. Product information BOTOX 2015. Available from: http://www.allergan.com/assets/pdf/botox_pi.pdf

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.